Baird analyst Eric Coldwell raised the firm’s price target on McKesson to $445 from $440 and keeps an Outperform rating on the shares. The analyst said their commentary at a conference confirmed U.S. Pharmaceutical utilization and pricing trends are roughly as expected
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MCK: